PT  - JOURNAL ARTICLE
AU  - Khera, Rohan
AU  - Scheumie, Martijn J
AU  - Lu, Yuan
AU  - Ostropolets, Anna
AU  - Chen, Ruijun
AU  - Hripcsak, George
AU  - Ryan, Patrick B
AU  - Krumholz, Harlan M
AU  - Suchard, Marc A
TI  - RESEARCH PROTOCOL: Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus
AID  - 10.1101/2021.09.27.21264139
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.27.21264139
4099  - http://medrxiv.org/content/early/2021/09/29/2021.09.27.21264139.1.short
4100  - http://medrxiv.org/content/early/2021/09/29/2021.09.27.21264139.1.full
AB  - Background Therapeutic options for type 2 diabetes mellitus (T2DM) have expanded over the last decade with the emergence of sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP1) receptor agonists, which reduced the risk of major cardiovascular events in randomized controlled trials (RCTs). Cardiovascular evidence for older second-line agents, such as sulfonylureas, and direct head-to-head comparisons, including with dipeptidyl peptidase 4 (DPP4) inhibitors, are lacking, leaving a critical gap in our understanding of the relative effects of T2DM agents on cardiovascular risk and on patient-centered safety outcomes.Methods and Analysis The Large-Scale Evidence Generations Across a Network of Databases for T2DM (LEGEND-T2DM) initiative is a series of systematic, large-scale, multinational, real-world comparative cardiovascular effectiveness and safety studies of all 4 major second-line anti-hyperglycemic agents including SGLT2 inhibitor, GLP1 receptor agonist, DPP4 inhibitor and sulfonylureas. LEGEND-T2DM will leverage the Observational Health Data Science and Informatics (OHDSI) community that provides access to a global network of administrative claims and electronic health record (EHR) data sources. Committed data partners represent 190 million patients in the US and about 50 million internationally. LEGEND-T2DM will identify all adult, T2DM patients who newly initiate a traditionally second-line T2DM agent, including individuals with and without established cardiovascular disease. Using an active comparator, new-user cohort design, LEGEND-T2DM will execute all pairwise class-vs-class and drug-vs-drug comparisons in each data source that meet a minimum patient count of 1,000 per arm and extensive study diagnostics that assess reliability and generalizability through cohort balance and equipoise to examine the relative risk of cardiovascular and safety outcomes. The primary cardiovascular outcomes include a 3-point and a 4-point composite of major adverse cardiovascular events, and series of safety outcomes. The study will pursue data-driven, large-scale propensity adjustment for measured confounding, a large set of negative control outcome experiments to address unmeasured and systematic bias.Ethics and Dissemination The study ensures data safety through a federated analytic approach and follows research best practices, including prespecification and full disclosure of hypotheses tested and their results. LEGEND-T2DM is dedicated to open science and transparency and will publicly share all our analytic code from reproducible cohort definitions through turn-key software, enabling other research groups to leverage our methods, data, and results in order to verify and extend our findings.Competing Interest StatementThis study is undertaken within Observational Health Data Sciences and Informatics (OHDSI), an open collaboration. RK is a founder of Evidence2Health and receives grant funding from the US National Institutes of Health. MJS and PBR are employees of Janssen Research and Development and shareholders in John & Johnson. GH receives grant funding from the US National Institutes of Health and the US Food & Drug Administration and contracts from Janssen Research and Development. HMK receives grants from the US Food & Drug Administration, Medtronics, and Janssen Research and Development, is co-founder of HugoHealth and Refactor Health, and chairs the Cardiac Scientific Advisory Board for UnitedHealth. MAS receives grant funding from the US National Institutes of Health, the US Department of Veterans Affairs, and the US Food & Drug Administration and contracts from Janssen Research and Development and IQVIA. Funding StatementThe proposal was partially funded through the National Institutes of Health grants K23 HL153775 and R01 LM006910 and an Intergovernmental Personnel Act agreement with the US Department of Veterans Affairs. The funders had no role in the design and conduct of the proposal; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB approval or waiver statements from partners are included in Table 4. The study uses a federated analytic model that is exempt from the purview of the IRB for data partners.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe study relies on a federated analytic model where the data reside with the source. The code for the study will be publicly available but the data can only be obtained in partnership with individuals and organizations included as data sources.CDMCommon data modelDPP4Dipeptidyl peptidase-4GLP1Glucagon-like peptide-1IRBInstitutional review boardLEGENDLarge-scale Evidence Generation and Evaluation across a Network of DatabasesMACEMajor adverse cardiovascular eventMDRRMinimum detectable risk ratioOHDSIObservational Health Data Science and InformaticsOMOPObservational Medical Outcomes PartnershipPSPropensity scoreRCTRandomized controlled trialSGLT2Sodium-glucose co-transporter-2T2DMType 2 diabetes mellitus